Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

3 days ago 1

Healthcare

Prime Minister Scott Morrison Announces Deal With AstraZeneca To Supply Potential COVID-19 Vaccine

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions to strike a licensing deal with the company for its lung cancer drug ivonescimab, a potential rival

Recommended For You

More Trending News

Read Entire Article

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

Recommended For You

More Trending News

Related

U.S. stocks in the red as investors assess Trump's tariff pl...

Trump Media launches its TV streaming service globally

Ambac, Oaktree extend pact for Financial Guarantee business

Electric stuff: BYD starts vehicle production in Brazil as i...

Progressive cut at Morgan Stanley on intensifying competitio...

KalVista Pharmaceuticals rises after FDA nod for Ekterly

Northern Dynasty surges on settlement talks over EPA veto of...

Smartphone sales to China dip as Apple holds bulk of non-dom...

Amazon Prime Day is forecast by Adobe to be a smashing succe...

CVS Health declares $0.665 dividend

Dating apps are doomed because Gen Z is locked in on meet-cu...

Voyager Technologies rated Buy in new research coverage by B...

CoreWeave to acquire Core Scientific in all-stock deal

BofA reinstates coverage on top U.S. telecoms

Canadian government talking to Rio Tinto about cash flow hel...

Wolfspeed appoints Gregor van Issum as CFO

ATS Corporation CEO Andrew Hider steps down; Ryan McLeod app...

IonQ announces pricing of $1B equity offering

Carnival corporation launches new senior unsecured notes off...

Fortitude Gold declares $0.01 dividend

Trending

Popular

Biggest weekly communication services gainers: Meta Platform...

Re: No shortage of bombs, but scarcity of everything to star...